Vedolizumab's Real-World impact on Crohn's disease explored

NCT ID NCT05192863

Completed Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed observational study followed 72 adults with moderate to severe Crohn's disease who were starting vedolizumab treatment. The goal was to see if the drug could lead to complete remission—meaning no symptoms, normal inflammation markers, and healed bowel walls—after 12 months. Researchers used ultrasound to check bowel inflammation, alongside standard symptom scores and lab tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN'S DISEASE

Contacts and locations

Locations

A.O.U. Federico II

Naples, 80131, Italy
ASST Fatebenefratelli Sacco

Milan, 20157, Italy
Fondazione Ca' Granda Ospedale Maggiore Policlinico

Milan, 20122, Italy
Hadassah Medical Center

Jerusalem, 9112001, Israel
Ospedale ASST Rhodense

Rho, Milano, 20017, Italy
Ospedale San Raffaele

Milan, 20132, Italy
Rabin Medical Center

Petah Tikva, 4941492, Israel
Sheba Medical Center

Ramat Gan, 5262000, Israel
University of Calgary

Calgary, Alberta, T2N 4N1, Canada
University of Saskatchewan

Saskatoon, Saskatchewan, S7N 0W8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.